Relationship of dyslipidemia and autovenous femoro-popliteal bypass outcome
https://doi.org/10.52727/2078-256X-2022-18-1-33-37
Abstract
The effect of blood lipid profile levels on the service life of autovenous femoral-popliteal bypass has not been fully studied. The aim of the study was to assess the effect of lipid metabolism disorders on the long-term results of autovenous femoral-popliteal bypass surgery.
Material and methods. Results of treatment of 648 patients who underwent autovenous femoral-popliteal bypass grafting were analyzed. In accordance with the outcome of surgical treatment, the patients were divided into 2 clinical groups: the first group (290 patients) included patients who, according to the instrumental methods of research in the long-term period, had occlusion of the autovenous femoral-popliteal bypass, the second group (358 people) included patients whose autovenous conduit was passable. The average service life of the autovenous femoral-popliteal bypass in patients of the first group was 78 ± 18 months. Patients in the first and second groups aged 64.5 ± 7.9 and 64.9 ± 8.6 years, respectively, p = 0.58, males prevailed (n = 503, 77.62 %).
Results. Analysis of lipidogram data showed higher content of total cholesterol, low density lipoprotein, triacylglycerol, atherogenic coefficient in patients of the first clinical group. Dyslipidemia was recorded in 256 (88.3 %) patients of the first group and 190 patients of the second group (53.1 %), p = 0.001. The patency time of the autovenous conduit in patients of the first group, who was diagnosed with dyslipidemia, was 68.15 months, without this complication – 105.84 months.
Conclusions. Dyslipidemia and hyperlipidemia significantly reduce the lifespan of the autovenous femoral-popliteal bypass. The work has no funding
About the Authors
А. S. Artemova
Almazov National Medical Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
Anastasia S. Artemova, cardiovascular surgeon, postgraduate student of the Department of Cardiovascular Surgery
197341, St. Petersburg, Akkuratov str., 2
M. A. Сhernyavsky
Almazov National Medical Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
Mikhail A. Сhernyavsky, MD, Chief Researcher, cardiovascular surgeon, Head
197341, St. Petersburg, Akkuratov str., 2
References
1. Campia U., Gerhard-Herman M., Piazza G., Goldhaber S.Z. Peripheral artery disease: past, present, and future. Am. J. Med., 2019; 132 (10): 1133–1141. doi: 10.1016/j.amjmed.2019.04.043
2. Eid M.A., Mehta K.S., Goodney P.P. Epidemiology of peripheral artery disease. Semin. Vasc. Surg., 2021; 34 (1): 38–46. doi: 10.1053/j.semvascsurg.2021.02.005
3. Duff S., Mafilios M.S., Bhounsule P., Hasegawa J.T. The burden of critical limb ischemia: a review of recent literature. Vasc. Health Risk Manag., 2019; 15: 187–208. doi: 10.2147/VHRM.S209241
4. Candan Ö., Gündüz S., Şahin M. Revascularization of superficial femoral artery due to chronic total occlusion: Collateral approach. Turk. Kardiyol. Dern. Ars., 2018; 46 (8): 714–717. doi: 10.5543/tkda.2018.10.5543/tkda.2017.96920
5. Davies M.G., El-Sayed H.F. Outcomes of native superficial femoral artery chronic total occlusion recanalization after failed femoropopliteal bypass. J. Vasc. Surg., 2017; 65 (3): 726–733. doi: 10.1016/j.jvs.2016.09.021
6. Dorigo W., Piffaretti G., Fargion A., Rivolta N., Bush R.L., Giacomelli E., Guttadauro C., Castelli P., Pratesi C. A retrospective comparison between hybrid treatment and prosthetic above-the-knee femoro-popliteal bypass in the management of the obstructive disease of the superficial femoral artery. World J. Surg., 2020; 44 (10): 3555–3563. doi: 10.1007/s00268-020-05616-w
7. Sigvant B., Lundin F., Wahlberg E. The risk of disease progression in peripheral arterial disease is higher than expected: a metaanalysis of mortality and disease progression in peripheral arterial disease. Eur. J. Vasc. Endovasc. Surg., 2016; 51: 395–403.
8. Глушков Н.И., Иванов М.А., Пуздряк П.Д., Самко К.В., Исакова А.А., Артемова А.С. Метаболические нарушения и итоги реконструктивных вмешательств у больных периферическим атеросклерозом. Вестн. Сев.-Зап. гос. мед. ун-та им. И.И. Мечникова, 2019; 11 (3): 33–40. doi: 10.17816/mechnikov201911333-40
9. Aday A.W., Everett B.M. Dyslipidemia profiles in patients with peripheral artery disease`. Curr. Cardiol. Rep., 2019; 21 (6): 42. doi: 10.1007/s11886-019-1129-5
10. Taher R., Sara J.D., Heidari B., Toya T., Lerman L.O., Lerman A. Metabolic syndrome is associated with peripheral endothelial dysfunction amongst men. Diabetes Metab. Syndr. Obes., 2019; 12: 1035–1045. doi: 10.2147/DMSO.S204666
11. Глушков Н.И., Иванов М.А., Апресян А.Ю., Пуздряк П.Д., Артемова А.С. Влияние метаболического синдрома на исходы реконструкций у больных с инфраингвинальной артериальной болезнью. Вестн. Сев.-Зап. гос. мед. ун-та им. И.И. Мечникова, 2018; 10 (3): 54–59. doi: 10.17816/mechnikov201810354-59
Review
For citations:
Artemova А.S., Сhernyavsky M.A. Relationship of dyslipidemia and autovenous femoro-popliteal bypass outcome. Ateroscleroz. 2022;18(1):33-37. (In Russ.) https://doi.org/10.52727/2078-256X-2022-18-1-33-37
Views:
185
Email this article 